Has a company taken a peptide-conjugated oligonucleotide treatment to commercial market yet or is it still a fairly academic science ?
Hoping some posters with more of a medical science background can share their insight into the maturity of the technology .
Ann: Kidney Disease Drug Candidate Progressing to Human Trials, page-20
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $886.5M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.0¢ | 18.5¢ | $142.7K | 751.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 204334 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 345272 | 11 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| PYC (ASX) Chart |